百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02615 百利天恒

待上市 02-06 16:00:00

0.000

+0.000

--

最高0.000	最低0.000	成交量0.00
今开0.000	昨收0.000	日振幅0.00%
总市值0.00	流通市值0.00	总股本4.22亿
成交额0.00	换手率0.00%	流通股本4.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1770364800000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"02-06 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.204,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1770341400000,1770350400000],[1770354000000,1770364800000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动；\n2、约30.0%或905.2百万港元将用于建立全球供应链，主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金；\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":281,"timestamp":1770361200000,"preClose":282.83,"halted":0,"volume":1278300,"delay":0,"premium":"-100.00"}},"requestUrl":"/m/hq/s/02615","defaultTab":"news","newsList":[{"id":"2608822501","title":"百利天恒回购32万股 金额9985万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608822501","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608822501?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:17","pubTimestamp":1770113866,"startTime":"0","endTime":"0","summary":"2月3日，百利天恒（688506）发布公告，截至2026年1月31日，公司已回购32万股，占总股本的0.08%，回购资金总额为9985万元，回购价格区间为279.72元/股至345.24元/股。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033640244377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","02615","91194","688506"],"gpt_icon":0},{"id":"2608981289","title":"百利天恒：预计2025年亏损约11亿元，共有17款创新药处于临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2608981289","media":"财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608981289?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:02","pubTimestamp":1770019332,"startTime":"0","endTime":"0","summary":"近日，百利天恒发布公告称，公司预计2025年营业收入约25亿元，同比减少57.06%左右；预计净亏损约11亿元，同比减少129.67%左右。截至报告期末，公司共有17款创新药处于临床试验阶段。报告期内收入下降主要原因为上年同期收到BMS首付款所确认的知识产权收入大于报告期内确认的里程碑收入。综上，公司2025年营业收入、归属于母公司所有者的净利润、归属于母公司所有者的扣除非经常性损益的净利润同比减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202160519a4726c19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202160519a4726c19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91194","BK1161","BK1574","02615","06978"],"gpt_icon":0},{"id":"2608838285","title":"百利天恒目标价涨幅近376% 金辰股份评级被调低丨券商评级观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2608838285","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608838285?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:19","pubTimestamp":1769995154,"startTime":"0","endTime":"0","summary":"南财投研通数据显示，1月26日至2月1日，券商给予上市公司目标价共103次，按最新收盘价计算，目标价涨幅排名居前的公司有百利天恒、泽璟制药、长城汽车，目标价涨幅分别为375.97%、88.56%、83.66%，前两者分别属于化学制药行业，后者属于乘用车行业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638055674.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638055674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603396","688506","91194","02615"],"gpt_icon":0},{"id":"2608886409","title":"股市必读：百利天恒（688506）预计2025年全年营业收入25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608886409","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608886409?lang=zh_cn&edition=full","pubTime":"2026-02-02 02:33","pubTimestamp":1769970791,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，百利天恒报收于277.75元，下跌0.3%，换手率0.42%，成交量1.7万手，成交额4.8亿元。业绩披露要点业绩预告百利天恒发布业绩预告，预计2025年全年归属净利润亏损约11亿元；扣非后净利润亏损约12亿元；营业收入预计为25亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","02615"],"gpt_icon":0},{"id":"2607432016","title":"百利天恒：预计2025年净亏损11亿元 同比转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2607432016","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607432016?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:02","pubTimestamp":1769767349,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月30日，百利天恒(688506.SH)公告称，预计2025年度归属于上市公司股东的净利润为-11.00亿元左右，上年同期为盈利37.08亿元，同比转亏。报告期内，公司持续加大研发投入，导致研发投入同比增幅较大。截至报告期末，公司共有17款创新药处于临床试验阶段（其中6款创新药处于全球临床试验）。公司正在全球范围内开展100余项创新药临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303637105727.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637105727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","02615","688506","BK0239"],"gpt_icon":0},{"id":"2606785019","title":"上半年封神的医药女神，翻车了","url":"https://stock-news.laohu8.com/highlight/detail?id=2606785019","media":"易简财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606785019?lang=zh_cn&edition=full","pubTime":"2026-01-27 18:57","pubTimestamp":1769511478,"startTime":"0","endTime":"0","summary":"近期，医药女神们的四季报披露，张韡、赵蓓等人的四季度业绩均陷入亏损。医药女神葛兰，持仓始终集中在大市值医药龙头、CXO和创新药三大主流赛道上。另一医药女神赵蓓，其管理代表作工银前沿医疗A，第四季度增持新诺威、科伦药业，减持药明康德、恒瑞医药，组合更加均衡。第四季度，市场回调后，他集中资金加仓核心标的，大幅增持迪哲医药，同时增持联影医疗、奕瑞科技等高端器械。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127190423a6b2cab2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127190423a6b2cab2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01530","BK1574","BK1515","09939","BK1576","BK1161","06160","BK1141","02196","02615","01276","03759","03347","02359"],"gpt_icon":0},{"id":"2606272282","title":"华福证券：医药生物业新技术全面突破 战略看多中国创新出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2606272282","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606272282?lang=zh_cn&edition=full","pubTime":"2026-01-27 11:01","pubTimestamp":1769482871,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华福证券发布研报称，2025年中国创新药全球竞争力凸显，出海交易创新高，多家企业扭亏为盈。战略看多中国创新出海。华福证券主要观点如下：国内复盘：全球竞争力凸显，企业扭亏为盈+管线出海价值新高度2025创新药指数大涨，Biopharma和Biotech持仓比例显著提升，核心驱动因素是中国创新药全球竞争力凸显。创新药市场份额快速提升，肿瘤与免疫领域创新药份额超32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127110355a6b10694&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127110355a6b10694&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","01530","09606","06955","02162","01276","06160","HK0000165453.HKD","01093","09887","01801","06938","02096","BK1593","BK1574","BK1583","02157","BK1161","01672","09926","02615"],"gpt_icon":0},{"id":"2606176278","title":"23股获推荐 百利天恒目标价涨幅超300%丨券商评级观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2606176278","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606176278?lang=zh_cn&edition=full","pubTime":"2026-01-27 09:09","pubTimestamp":1769476169,"startTime":"0","endTime":"0","summary":"南财投研通数据显示，1月26日，券商给予上市公司目标价共9次，按最新收盘价计算，目标价涨幅排名居前的公司有百利天恒、洛阳钼业、三七互娱，目标价涨幅分别为368.30%、37.88%、29.53%，分别属于化学制药、工业金属、游戏行业。从券商推荐家数来看，1月26日有23家上市公司得到券商推荐，其中建发股份、首华燃气、花园生物等获得1家推荐。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601273631460230.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273631460230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","02615","91194"],"gpt_icon":0},{"id":"2606758216","title":"2025第十一届中国最具影响力医药企业百强榜发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2606758216","media":"江南时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606758216?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:16","pubTimestamp":1769418960,"startTime":"0","endTime":"0","summary":"2026年1月26日，由董事会网、亚布力智库联合主办的“2025第十一届中国最具影响力医药企业百强榜”正式揭晓。在医药产业从“规模扩张”向“创新驱动”转型的关键期，本届百强榜的发布具有多重行业价值，成为解读中国医药产业格局的重要窗口。从本届榜单不难看出，中国医药产业正呈现“创新集聚、分化加剧、区域协同”的发展趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126172516a456f932&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126172516a456f932&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","00874","03692","01801","09939","BK1515","01530","02607","01477","00460","02315","06160","BK1574","06821","BK1191","01276","02615","02196"],"gpt_icon":0},{"id":"2605054604","title":"百利天恒（688506）披露召开2026年第一次临时股东会通知，1月23日股价下跌0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605054604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605054604?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:20","pubTimestamp":1769178004,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，百利天恒报收于290.61元，较前一交易日下跌0.38%，最新总市值为1199.85亿元。该股当日开盘291.75元，最高294.99元，最低285.33元，成交额达5.94亿元，换手率为0.51%。近日，四川百利天恒药业股份有限公司发布《关于召开2026年第一次临时股东会的通知》。公告显示，公司定于2026年2月9日召开2026年第一次临时股东会，会议采取现场投票与网络投票相结合方式。股权登记日为2026年2月2日。股东可委托代理人出席。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","02615","91194"],"gpt_icon":0},{"id":"2605351429","title":"葛兰、张坤、谢治宇等基金经理2025年4季度最新持仓出炉！中际旭创、新易盛成前2重仓股！","url":"https://stock-news.laohu8.com/highlight/detail?id=2605351429","media":"公募排排网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605351429?lang=zh_cn&edition=full","pubTime":"2026-01-23 11:59","pubTimestamp":1769140766,"startTime":"0","endTime":"0","summary":"与张坤不同，谢治宇的持仓在2025年充满科技感。往右滑动可查看其他季度的持仓谢治宇在4季度对海外算力、半导体设备等领域进行了重点配置。前十大重仓股进一步集中！截至2025年底，葛兰前十大持仓占比从第1季度的55.30%上升4季度至64.20%，对医药股的持仓进一步集中，显示了其坚定的医药赛道投资风格。2025年度公募人气榜揭晓！葛兰、刘旭、张坤前3！2025年全年热销榜出炉！复盘2025年十大投资热点！QDII基金10强出炉！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123131836a6a37ec0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123131836a6a37ec0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YS42.EUR","SG9999002562.SGD","LU1044876610.USD","LU0878005551.USD","LU0561508036.HKD","LU0871576103.HKD","LU0918141705.HKD","LU2476274308.USD","03145","LU0823426308.USD","LU0348805143.USD","82318","LU2778985437.USD","01880","01276","LU1642822792.SGD","LU0051755006.USD","02899","02615","HPAD.SI","LU0359201612.USD","LU0708995583.HKD","BK1521","IE00B29SXG58.USD","LU0052750758.USD","02318","LU1046422090.SGD","LU0797268264.HKD","02359","LU0572944931.SGD","SG9999004220.SGD","LU0531971595.HKD","LU0197773160.USD","601318","LU0359202008.SGD","LU0819123356.HKD","LU1051768304.USD","IE00BVYPNQ40.USD","LU0228367735.SGD","LU0370786039.SGD","09988","LU0384037296.USD","LU1719994722.HKD","LU0882747503.HKD","PAImain","LU0084288322.USD","03750","PNGAY","LU0348784397.USD","IE00BYV24P56.USD","LU0359201885.HKD","03347","LU0823426480.USD","LU1051769294.HKD","HK0000306685.HKD","LU1720050803.USD","LU0634319403.HKD","LU1282649141.HKD"],"gpt_icon":0},{"id":"2605593460","title":"广发基金吴兴武旗下广发保健A年报最新持仓，重仓百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2605593460","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605593460?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:58","pubTimestamp":1769079533,"startTime":"0","endTime":"0","summary":"证券之星消息，1月22日广发基金旗下吴兴武管理的广发医疗保健股票型基金公布年报，近1年净值增长率16.73%。与上一季度相比，该基金前十大重仓股新增海思科，三生国健，信立泰；其中百利天恒持仓占比7.26%，为该基金第一大重仓股；新诺威，百济神州，一品红等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200033876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","02615","91194"],"gpt_icon":0},{"id":"2605467090","title":"于启明2025年四季度表现，嘉合锦鹏添利混合A基金季度跌幅0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605467090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605467090?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:50","pubTimestamp":1769079037,"startTime":"0","endTime":"0","summary":"证券之星消息，截止2025年四季度末，基金经理于启明旗下共管理4只基金，本季度表现最佳的为嘉合锦鹏添利混合A，季度净值跌0.14%。持有期间的估算收益率为438.95%，持有期间景嘉微在2015年到2016年的年报归属净利润增幅达18.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200033632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1237","02615","02648"],"gpt_icon":0},{"id":"2605170450","title":"1月21日百利天恒现269.67万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2605170450","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605170450?lang=zh_cn&edition=full","pubTime":"2026-01-21 17:41","pubTimestamp":1768988509,"startTime":"0","endTime":"0","summary":"证券之星消息，1月21日百利天恒发生大宗交易，交易数据如下：大宗交易成交价格303元，成交0.89万股，成交金额269.67万元，买方营业部为中信证券华南股份有限公司广州琶洲宸悦路证券营业部，卖方营业部为中国国际金融股份有限公司北京建国门外大街证券营业部。近三个月该股共发生3笔大宗交易，合计成交310.0手。截至2026年1月21日收盘，百利天恒报收于303.0元，下跌0.33%，换手率0.32%，成交量1.28万手，成交额3.89亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100029704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","02615","688506","91194"],"gpt_icon":0},{"id":"2605110936","title":"继鼻咽癌后瞄准食管鳞癌二线治疗 百利天恒双抗ADC第二项上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2605110936","media":"每经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605110936?lang=zh_cn&edition=full","pubTime":"2026-01-20 20:19","pubTimestamp":1768911590,"startTime":"0","endTime":"0","summary":"1月20日，CDE官网披露，百利天恒旗下核心管线iza-bren的第二项上市申请获得受理。食管鳞癌的后线治疗是临床上面临的主要挑战。2025年11月，鼻咽癌适应证的新药上市申请获CDE受理，有望在2026年率先实现商业化。肺癌、乳腺癌等适应证预计将于2026年开始递交新药上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012020200997a2989d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012020200997a2989d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91194","HK0000320264.USD","HK0000306701.USD","02615","02696","HK0000306685.HKD","HK0000165453.HKD","HK0000320223.HKD","BK1161"],"gpt_icon":0},{"id":"2604185671","title":"百利天恒iza-bren用于治疗复发性或转移性食管鳞癌的药品上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2604185671","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604185671?lang=zh_cn&edition=full","pubTime":"2026-01-20 20:14","pubTimestamp":1768911252,"startTime":"0","endTime":"0","summary":"百利天恒iza-bren用于治疗复发性或转移性食管鳞癌的药品上市申请获得受理","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601203624898124.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624898124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","02615","688506","BK0239"],"gpt_icon":0},{"id":"2604906375","title":"贵州茅台等191股获推荐，百利天恒目标价涨幅超300%丨券商评级观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2604906375","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604906375?lang=zh_cn&edition=full","pubTime":"2026-01-19 09:53","pubTimestamp":1768787617,"startTime":"0","endTime":"0","summary":"21财经1月19日电，南财投研通数据显示，1月12日至1月18日，券商给予上市公司目标价共92次，按最新收盘价计算，目标价涨幅排名居前的公司有百利天恒、湖南裕能、华立科技，目标价涨幅分别为319.47%、85.81%、58.27%，分别属于化学制药、电池、文娱用品行业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601193623000868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03189","600519","91194","688506","02615","83189"],"gpt_icon":0},{"id":"2604749925","title":"每周股票复盘：百利天恒（688506）股东OAP拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2604749925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604749925?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:38","pubTimestamp":1768682289,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，百利天恒报收于315.16元，较上周的343.9元下跌8.36%。公司公告汇总四川百利天恒药业股份有限公司关于持股5%以上股东减持股份计划公告截至公告披露日，OAP III Limited持有公司6.91%股份，计划自公告披露之日起十五个交易日后三个月内，通过集中竞价方式减持不超过公司总股本1.00%的股份，即不超过4,128,738股，减持原因为自身资金需求。本次减持计划符合相关法律法规及承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","688506","BK0239"],"gpt_icon":0},{"id":"2603492998","title":"百利天恒股东OAP III(HK)Limited拟减持不超1%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603492998","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603492998?lang=zh_cn&edition=full","pubTime":"2026-01-16 19:54","pubTimestamp":1768564470,"startTime":"0","endTime":"0","summary":"1月16日，百利天恒（688506）发布公告，股东OAPIII(HK)Limited因自身资金需求，计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持不超过413万股公司股份，占公司总股本的1%。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622097950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","91194","III","688506","02615","BK4134"],"gpt_icon":0},{"id":"2603937939","title":"2026年JPM大会诺华、阿斯利康、辉瑞等巨头超百亿美元交易频现，中国资产成最大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937939","media":"药厂那点事儿","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603937939?lang=zh_cn&edition=full","pubTime":"2026-01-16 07:05","pubTimestamp":1768518317,"startTime":"0","endTime":"0","summary":"巨头交易频现，中国资产备受青睐。诺华公司周二下午宣布了一项针对中国生物技术公司泽璟生物的许可交易。再生元计划在2026年公布该药用于肥胖治疗的中国3期临床试验结果，并启动全球3期临床开发计划。截至2025年第三季度，19家大型制药公司现金储备总额超过1700亿美元，2025年前三季度产生了约1400亿美元的自由现金流，为大规模并购交易提供了充足的资金支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","01477","02359","BK1161","09688","02268","06978","BK1574","06855","ZLAB","02615","02269","BK1191","01530"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baili-pharm.com","compareEarnings":[{"period":"1week","weight":-0.0302},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0121},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.2713},{"period":"ytd","weight":0.0363}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家聚焦于全球生物医药前沿领域，立足于解决临床未被满足的需求，具备包括小分子化学药、大分子生物药及ADC药物的全系列药品研究开发能力，并拥有从中间体、原料药到制剂一体化优势的、覆盖“研发—生产—营销”完整全生命周期商业化运营能力的生物医药企业。公司拥有两大业务板块,分别为创新生物药业务和化药制剂、中成药制剂业务板块。公司主要产品:丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","exchange":"SEHK","name":"百利天恒","nameEN":"BIOKIN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,02615,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}